Actively Recruiting
Phase II Study of Potato-Based Resistant Starch and Deferasirox for Patients Undergoing Allogeneic Stem Cell Transplant to Improve Outcomes
Led by University of Michigan Rogel Cancer Center · Updated on 2026-07-21
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and early effectiveness of combining a commercially available potato-based resistant starch with iron chelation therapy in patients undergoing allogeneic stem cell transplantation alloHCT. The study aims to reduce the rates of acute graft versus host disease GVHD and improve graft versus host diseaserelapse-free survival GRFS at 12 months post-transplant by restoring intestinal health. Participants will receive iron chelation therapy with deferasirox starting 14 days before transplantation and continuing through day 100. The resistant potato starch RPS treatment begins 6 days before transplantation and also continues through day 100, with patients taking 20g twice daily. All subjects are enrolled in one group receiving both treatments. Throughout the study, participants will be monitored for survival without GVHD or relapse up to one year after transplantation. Researchers will assess rates of acute and chronic GVHD, length of event-free survival, and overall safety. The total involvement includes treatment through day 100 and follow-up for outcomes up to one year.
CONDITIONS
Brief Title
Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
Research Team
M
Mary Riwes
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
